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of when a diagnostic test can safely be used to rule out 
tuberculous meningitis. 
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Performance of Xpert MTB/RIF Ultra: a matter of dead or alive
In our opinion, the implementation of the Xpert 
MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) since 2010 
has revolutionised molecular diagnosis of (multidrug-
resistant) tuberculosis. Xpert combines early diagnosis 
of tuberculosis with direct detection of rifampicin 
resistance, but the limitations of the assay are its 
suboptimal sensitivity and high rate of false positivity in 
low-prevalence settings. To overcome these limitations, 
the assay was re-engineered to increase diagnostic 
sensitivity and improve specificity in the detection of 
rifampicin resistance. The resulting Xpert MTP/RIF Ultra 
(Xpert Ultra) assay is run on the same device as Xpert and 
requires only a software upgrade.1 In The Lancet Infectious 
Diseases, Susan Dorman and colleagues2 report the results 
of a comparison between Xpert Ultra with Xpert assay 
performance on sputum samples from 1753 patients 
tested at ten reference laboratories in eight tuberculosis 
high-endemic countries.
Xpert and Xpert Ultra had roughly similar performance 
in the detection of rifampicin resistance, but Xpert 
Ultra had a higher overall sensitivity than Xpert 
(88% [95% CI 85–91] with Xpert Ultra vs 83% [79–86] 
with Xpert)—the difference being more pronounced in 
smear-negative cases (63% [54–71] vs 46% [37–55]) and 
in HIV co-infected cases (90% [83–90] vs 77% [68–84]).2 
Xpert Ultra’s improved sensitivity was, however, 
associated with a 2% lower specificity than Xpert 
(96% [94–97] vs 98% [97–99]). The specificity of Xpert 
Ultra for detection of Mycobacterium tuberculosis was 
even lower in patients with previous tuberculosis or 
from high-incidence countries.
The increased sensitivity and reduced specificity of 
Xpert Ultra compared with Xpert translates into a higher 
negative predictive value but a lower positive predictive 
value. These effects, which seem counterintuitive, 
are shown in the figure in terms of Bayes’ theorem 
of conditional probabilities (figure). Compared with 
a useless test, a positive test result increases and 
a negative test result decreases the probability of 
tuberculosis, but to a different extent for Xpert and 
Xpert Ultra. In terms of percentage, the increase in 
sensitivity of Xpert Ultra exceeds the decrease in 
specificity.2 However, the number of participants with 
culture-negative sputum (n=977) was twice that of 
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participants with culture-positive sputum (n=462). The 
observed percentages thus correspond to an additional 
25 patients with positive-culture sputum diagnosed 
early by Xpert Ultra but not by Xpert, at a cost of 
26 additional false-positive Xpert Ultra results that were 
culture-negative.
We assume the observed excess of false-positive 
Xpert Ultra results can be explained by detection of 
DNA from non-viable M tuberculosis, a phenomenon 
previously shown for Xpert.3 The origin of M tuberculosis 
DNA in sputum in the absence of viable bacilli could 
be residual tuberculosis lesions after treatment, as 
prolonged excretion of M tuberculosis DNA has been 
demonstrated.4 Perhaps we should view tuberculosis 
as a spectrum of diseases,5,6 with subclinical, 
self-contained tuberculosis or even a stage of latent 
tuberculosis as other possible sources of M tuberculosis 
DNA in sputum.
In the study by Dorman and colleagues,2 positive 
results due to DNA from dead bacilli are only named 
false positive because the gold standard was culture. 
Although both Xpert and Xpert Ultra are designed to 
detect M tuberculosis DNA, dead or alive, the clinical 
question is whether viable M tuberculosis is present. 
Thus, the tests answer a different question. By contrast, 
a study by Bahr and colleagues7 compared Xpert 
Ultra with Xpert for detection of M tuberculosis in 
cerebrospinal fluid, showing that Xpert Ultra’s sensitivity 
was superior even compared with culture. The specificity 
of both tests was very high and comparable because 
the gold standard was a clinical case definition, and 
detection of M tuberculosis DNA was always considered 
significant. We show the unambiguous advantages of 
Xpert Ultra (figure), which was named a possible game 
changer in that setting.8
The ultimate cause of detection of DNA from 
dead bacilli is its high stability, which is just what 
palaeomicrobiology makes use of; M tuberculosis DNA 
has even been detected in millennia-old human remains.9 
Interestingly, the target region for such studies was 
IS6110, one of the two multicopy sequences for which 
additional primers were included in Xpert Ultra.1 A test 
that exclusively identifies viable M tuberculosis would be 
the solution, for example by detection of M tuberculosis 
mRNA or analysis of exhaled breath for organic volatile 
compounds of M tuberculosis.4,10 However, these methods 
never passed the research stage of development.
Based on a technical expert consultation, WHO states 
that Xpert Ultra can replace Xpert in all settings.11 
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Figure: Post-test probability of tuberculosis based on the sensitivity and 
specificity of Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) assays, as 
observed in two recent studies2,7
(A) Constructed using Xpert and Xpert Ultra sensitivity (0·83 vs 0·88) and specificity 
(0·98 vs 0·96) on sputum samples, as observed in the study by Dorman and 
colleagues.2 (B) Constructed using the sensitivity of Xpert (0·43) and Xpert 
Ultra (0·70) on cerebrospinal fluid, as observed in the study by Bahr and colleagues.7 
The specificity is arbitrarily set at 0·99 with the assumption that false-positive results 
in cerebrospinal fluid are highly unlikely, as explained by Bahr and colleagues.7 
The green lines indicate the post-test probability of tuberculosis using a test without 
diagnostic value, which equals the pre-test probability (x=y). The blue lines indicate 
the positive predictive value of Xpert (dashed line) and Xpert Ultra (continuous line), 
which is the proportion of true positive results. The red lines indicate the proportion 
of false-negative results for Xpert (dashed line) and Xpert Ultra (continuous line), 
which equals 1 minus the negative predictive value. The vertical dashed lines in each 
panel indicate the prevalence of tuberculosis in each study. The arrows between the 
blue lines indicate the change of the positive predictive value if Xpert Ultra replaces 
Xpert (decrease in panel A and increase in panel B). The arrows between the red lines 
indicate the change in the rate of false-negative results if Xpert Ultra replaces Xpert 
(decrease in both panels). The Bayes graph creator can be used to compare any 
two tests for which the sensitivity and specificity are known (appendix). See Online for appendix
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and unknowns.12 Metaphorically speaking, if Xpert is 
a knife, Xpert Ultra is a sharper knife. However, the 
trade-off of the higher sensitivity is a lower specificity, 
as is customary for diagnostic tests. We eagerly await 
additional studies and algorithms that assess Xpert 
Ultra’s improved sensitivity and solutions to avoid the 
trap of treating patients for dead bacilli.
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Pre-exposure prophylaxis is cost-effective for HIV in the UK
At the International AIDS Society (IAS) conference in Paris, 
France, in July, 2017, new data were presented showing a 
large reduction in HIV diagnoses in the UK’s largest sexual 
health clinic. 56 Dean Street in Soho (London, UK) saw a 
42% drop in new diagnoses between 2015 and 2016.1,2 
Similarly promising findings were reported in studies of 
clinics in France and Australia. This reduction is likely to be 
due to increased testing, earlier diagnosis, and immediate 
initiation onto HIV treatment at diagnosis,3 as well as 
increased availability of pre-exposure prophylaxis (PrEP) 
for HIV.
In The Lancet Infectious Diseases, Valentina Cambiano 
and colleagues4 directly address a key issue of PrEP: the 
cost-effectiveness of including it as part of the package of 
routine HIV care throughout the UK. The question is, given 
its budget impact, are the benefits of providing PrEP for 
men who have sex with men (MSM) likely to be greater or 
lower than the benefits associated with other health-care 
interventions, which will consequentially be forgone as a 
result of resources being committed to PrEP?
HIV incidence has been persistently high for years, 
particularly among MSM who, despite constituting 
a small percentage of the UK population, account for 
more than half of new HIV infections.5 The PROUD6 and 
IPERGAY7 trials have shown the high levels of effectiveness 
of PrEP in reducing HIV infections among MSM, providing 
compelling evidence for its clinical effectiveness.
By contrast with the optimism surrounding the clinical 
effectiveness of PrEP, however, the current mood around 
funding and provision of sexual health services in the UK 
is bleak. NHS England (which funds HIV treatment) had 
initially refused to pay for PrEP, arguing that responsibility 
for HIV prevention services laid with local authorities. 
Following a judicial review and subsequent rejection 
of that decision, NHS England announced it would 
provide PrEP to 10 000 patients, but only through a large 
implementation study in selected clinics from September, 
2017.8 Presented as a means to identify optimal ways of 
delivery, this decision has been viewed by many as simply 
a strategy to postpone access across the country.
Cambiano and colleagues4 deliver, to our knowledge, the 
most comprehensive PrEP modelling study ever done for 
the UK. The model is impressively calibrated to a wide range 
of data, reflecting what is currently known about patterns of 
Published Online 
October 17, 2017 
http://dx.doi.org/10.1016/ 
S1473-3099(17)30594-7
See Articles page 85
M
ar
cB
ru
xe
lle
